secwatch.observer — SEC 8-K summary
======================================

Issuer:     AETHLON MEDICAL INC (AEMD)
CIK:        0000882291
Form:       8-K
Filed at:   2025-02-12T23:59:59+00:00
Accession:  0001683168-25-000957
Event type: earnings
Sentiment:  neutral
Materiality: 0.55
Item codes: 2.02, 7.01, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

Aethlon Medical Q3 net loss narrows to $1.8M; first patient treated in Hemopurifier cancer trial
--------------------------------------------------------------------------------

- Cash balance $4.8M at Dec 31, 2024; operating expenses down 50% YoY to $1.8M.
- First Hemopurifier treatment completed Jan 29, 2025 at Royal Adelaide Hospital with no device-related issues.
- Net loss improved to $1.8M ($3.5M Q3 2023) due to cost cuts and lower separation expenses.
- Protocol amendment approved at all three Australian sites to accelerate enrollment by removing run-in period.
- Third clinical site (Genesis Care/Royal North Shore) to activate Feb 14, 2025; India site awaits CDSCO approval.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/882291/000168316825000957/0001683168-25-000957-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/882291/000168316825000957/aethlon_8k.htm
  HTML page:      https://secwatch.observer/filing/0001683168-25-000957

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer